Recent News

• 12.11.2025 - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
• 12.10.2025 - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
• 12.10.2025 - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
• 11.12.2025 - Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
• 10.31.2025 - Corbus Pharmaceuticals Announces Pricing of Public Offering
• 10.31.2025 - Corbus Pharmaceuticals Announces Pricing of Public Offering
• 10.30.2025 - Corbus Pharmaceuticals Announces Proposed Public Offering
• 10.30.2025 - Corbus Pharmaceuticals Announces Proposed Public Offering

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report
• 11.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - 8-K Current report
• 11.03.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.03.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]